Success Metrics

Active Trials
1(11%)

Phase Distribution

Ph phase_1
3
33%
Ph phase_2
4
44%
Ph phase_3
2
22%

Phase Distribution

3

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Other(5)

Detailed Status

unknown5
Not yet recruiting3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 24 (44.4%)
Phase 32 (22.2%)

Trials by Status

recruiting111%
unknown556%
not_yet_recruiting333%

Recent Activity

1 active trials
Showing 5 of 9
not_yet_recruitingphase_2

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

NCT06989671
not_yet_recruitingphase_3

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

NCT07134205
recruitingphase_3

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

NCT06735391
not_yet_recruitingphase_2

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

NCT06319313
unknownphase_2

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

NCT06089330
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06989671Phase 2

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not Yet Recruiting
NCT07134205Phase 3

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Not Yet Recruiting
NCT06735391Phase 3

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Recruiting
NCT06319313Phase 2

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Not Yet Recruiting
NCT06089330Phase 2

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Unknown
NCT05164848Phase 1

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Unknown
NCT05132777Phase 2

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Unknown
NCT04689100Phase 1

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Unknown
NCT04448379Phase 1

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9